The World's Greatest Investing Community
Results 1 - 10 of 17 : 1 2 Next
Buy, Sell, or Hold: Keryx Pharmaceuticals
Do the possible benefits outweigh the risks?
What to Look For With Seattle Genetics in 2012
The launch of its new drug Adcetris will be key.
Onyx Pharmaceuticals' Shares Jumped: What You Need to Know
Is this meaningful? Or just another movement?
Our investing community's latest pick to avoid: Vical.
The market shrugs off a solid quarter.
Are These Biotechs Creating Value?
What EVA momentum shows us about the folks running these biotech companies.
Now that's a good question, isn't it?
Insiders Are Buying Exelixis. Should You?
Maybe, but not because they're buying.
Technically, Dendreon Is a Buy
Assuming you pay attention to lines on a graph.
This Just In: Upgrades and Downgrades
Deutsche thinks Dendreon could go blockbuster.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK